Annual report
2914.TEDINET S100VH9B
Period2024-01-01 → 2024-12-31
Filed2025-03-26
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.15T | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.84T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.66T | 2022-01-01 → 2022-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.32T | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.09T | 2020-01-01 → 2020-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥323.5bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥672.4bn | 2023-01-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥233.8bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥621.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥593.5bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥472.4bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥420.1bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥179.2bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥482.3bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥442.7bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥338.5bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥310.3bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥182.6bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥485.3bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥444.2bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥340.2bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥312.0bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥8.37T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥7.28T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥6.55T | at 2022-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.77T | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.38T | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥4.52T | at 2024-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥3.37T | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥3.85T | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.91T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.62T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥3.77T | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥3.83T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥1.08T | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥1.04T | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥866.9bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥721.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥538.8bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥630.0bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥566.3bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥483.8bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥598.9bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥519.8bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥439.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥125.4bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥101.8bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥97.5bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥5.4bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥94.9bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥270.5bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥306.2bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥353.1bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥297.4bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥100.95 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥271.69 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥249.45 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥190.76 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥174.88 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥100.94 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥271.63 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥249.36 | 2022-01-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥190.68 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥174.8 | 2020-01-01 → 2020-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥2,121.33 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥2,157.46 | at 2023-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,994.78 | at 2022-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,583.1 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,421.92 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 45.0% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 52.6% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.1% | at 2022-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.6% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 46.9% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 4.7% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.1% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.9% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.7% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.0% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 53,593 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 53,239 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 52,640 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 55,381 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 58,300 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥530.2bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥537.3bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥542.2bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥592.2bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥596.9bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥6.1bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | ¥20.1bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥404.4bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥185.7bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥273.7bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥278.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥240.5bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥405.6bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥195.1bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥404.8bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥184.8bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥283.5bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥216.9bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥241.8bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.30T | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥2.29T | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥2.36T | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.49T | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.60T | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.09T | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥1.11T | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.21T | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.18T | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.37T | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥1.34T | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.39T | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥205.8bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥177.7bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥228.02 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥104.1 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥159.72 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥122.23 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥136.27 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥227.98 | 2024-01-01 → 2024-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥104.07 | 2023-01-01 → 2023-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥159.66 | 2022-01-01 → 2022-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥122.18 | 2021-01-01 → 2021-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥136.21 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥194 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥194 | 2023-01-01 → 2023-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥188 | 2022-01-01 → 2022-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥140 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥154 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥684.01 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥664.12 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥770.57 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥757.1 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥782.73 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 52.7% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.4% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.9% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 33.8% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.5% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.9% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.2% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,000,000,000 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,000,000,000 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,000,000,000 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,000,000,000 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,000,000,000 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 5,994 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 5,940 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 5,819 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 7,154 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 7,366 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 84
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-01-01 → 2024-12-31 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-12-31 | ¥4.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-12-31 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-12-31 | −¥57.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-12-31 | −¥57.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-12-31 | −¥48.4bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥3.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥3.5bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | ¥5m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | ¥5m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | ¥5m |
| Pharmaceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥7.0bn |
| Pharmaceuticalsreportable segment | employees | at 2024-12-31 | 1340 pure |
| Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥94.5bn |
| Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥94.5bn |
| Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥9.2bn |
| Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥9.2bn |
| Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥9.2bn |
| Processed Foodreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥6.1bn |
| Processed Foodreportable segment | employees | at 2024-12-31 | 4134 pure |
| Processed Foodreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥157.2bn |
| Processed Foodreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥157.2bn |
| Processed Foodreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥28m |
| Processed Foodreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥8.1bn |
| Processed Foodreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥8.1bn |
| Processed Foodreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥8.0bn |
| Tobaccoreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥135.0bn |
| Tobaccoreportable segment | employees | at 2024-12-31 | 47120 pure |
| Tobaccoreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥2.90T |
| Tobaccoreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥2.90T |
| Tobaccoreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥431m |
| Tobaccoreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥791.8bn |
| Tobaccoreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥791.8bn |
| Tobaccoreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥354.6bn |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥148.1bn |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥3.15T |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥3.15T |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥458m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥809.1bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥809.1bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥371.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-01-01 → 2023-12-31 | ¥6.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-12-31 | ¥4.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-12-31 | ¥1.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥2.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-12-31 | −¥46.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-12-31 | −¥46.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-12-31 | −¥29.9bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥3.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥3.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | ¥124m |
| Pharmaceuticalsreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥6.6bn |
| Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥94.9bn |
| Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥94.9bn |
| Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥17.4bn |
| Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥17.4bn |
| Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥17.4bn |
| Processed Foodreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥5.8bn |
| Processed Foodreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥153.9bn |
| Processed Foodreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥153.9bn |
| Processed Foodreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥31m |
| Processed Foodreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥6.8bn |
| Processed Foodreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥6.8bn |
| Processed Foodreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥7.7bn |
| Tobaccoreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥101.6bn |
| Tobaccoreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥2.59T |
| Tobaccoreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥2.59T |
| Tobaccoreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥393m |
| Tobaccoreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥749.8bn |
| Tobaccoreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥749.8bn |
| Tobaccoreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥677.1bn |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥114.0bn |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥2.84T |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥2.84T |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥425m |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥774.0bn |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥774.0bn |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥702.2bn |
| Pharmaceuticalsreportable segment | employees | at 2024-12-31 | 711 pure |
| Processed Foodreportable segment | employees | at 2024-12-31 | 28 pure |
| Tobaccoreportable segment | employees | at 2024-12-31 | 4764 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,237
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating profit loss IFRS | Prior1YearDuration_jpcrp030000-asr_E00492-000ProcessedFoodReportableSegmentMember | 7691000000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration_ReportableSegmentsMember | 702201000000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -29914000000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration_ReconcilingItemsMember | 124000000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration | 672410000000 | JPY |
| Finance income IFRS | Prior1YearDuration | 44414000000 | JPY |
| Finance costs IFRS | Prior1YearDuration | 95222000000 | JPY |
| Profit loss before tax IFRS | Prior1YearDuration | 621601000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000TobaccoReportableSegmentMember | 791773000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000PharmaceuticalsReportableSegmentMember | 9233000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000ProcessedFoodReportableSegmentMember | 8071000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_ReportableSegmentsMember | 809077000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -57214000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_ReconcilingItemsMember | 5000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration | 751868000000 | JPY |
| Amortization cost of acquired intangibles arising from business acquisitions IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000TobaccoReportableSegmentMember | 55683000000 | JPY |
| Amortization cost of acquired intangibles arising from business acquisitions IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Amortization cost of acquired intangibles arising from business acquisitions IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000ProcessedFoodReportableSegmentMember | － | JPY |
| Amortization cost of acquired intangibles arising from business acquisitions IFRS | CurrentYearDuration_ReportableSegmentsMember | 55683000000 | JPY |
| Amortization cost of acquired intangibles arising from business acquisitions IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Amortization cost of acquired intangibles arising from business acquisitions IFRS | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Amortization cost of acquired intangibles arising from business acquisitions IFRS | CurrentYearDuration | 55683000000 | JPY |
| Adjustment items income IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000TobaccoReportableSegmentMember | 5568000000 | JPY |
| Adjustment items income IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Adjustment items income IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000ProcessedFoodReportableSegmentMember | 446000000 | JPY |
| Adjustment items income IFRS | CurrentYearDuration_ReportableSegmentsMember | 6013000000 | JPY |
| Adjustment items income IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 9607000000 | JPY |
| Adjustment items income IFRS | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Adjustment items income IFRS | CurrentYearDuration | 15621000000 | JPY |
| Adjustment items costs IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000TobaccoReportableSegmentMember | 387074000000 | JPY |
| Adjustment items costs IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Adjustment items costs IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000ProcessedFoodReportableSegmentMember | 511000000 | JPY |
| Adjustment items costs IFRS | CurrentYearDuration_ReportableSegmentsMember | 387585000000 | JPY |
| Adjustment items costs IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 760000000 | JPY |
| Adjustment items costs IFRS | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Adjustment items costs IFRS | CurrentYearDuration | 388345000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000TobaccoReportableSegmentMember | 354584000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000PharmaceuticalsReportableSegmentMember | 9233000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E00492-000ProcessedFoodReportableSegmentMember | 8005000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_ReportableSegmentsMember | 371822000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -48367000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration_ReconcilingItemsMember | 5000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration | 323461000000 | JPY |
| Finance income IFRS | CurrentYearDuration | 69503000000 | JPY |
| Finance costs IFRS | CurrentYearDuration | 159198000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 233766000000 | JPY |
| Merchandise and finished goods ca IFRS | Prior1YearInstant | 189681000000 | JPY |
| Merchandise and finished goods ca IFRS | CurrentYearInstant | 211762000000 | JPY |
| Leaf tobacco ca IFRS | Prior1YearInstant | 519932000000 | JPY |
| Leaf tobacco ca IFRS | CurrentYearInstant | 599921000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |